查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947898

人工智慧疫苗研發市場分析及預測（至2035年）：按類型、產品類型、服務、技術、組件、應用、最終用戶、研發階段、部署類型和功能分類

AI for Vaccine Development Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Stage, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 340 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，人工智慧在疫苗研發領域的市場規模將從2024年的488億美元成長至4,496億美元，複合年成長率約為29.4%。該市場涵蓋人工智慧技術在疫苗研究、設計和生產的應用。人工智慧透過分析大量資料集、預測病原體結構和最佳化臨床試驗，加速疫苗研發進程。對新興疾病的快速反應需求以及人工智慧在縮短疫苗研發時間和降低成本方面的高效性，是推動市場成長的主要因素。關鍵趨勢包括用於抗原發現和個人化疫苗設計的人工智慧平台，這反映了精準醫療的發展趨勢。

人工智慧在疫苗研發領域的市場正經歷顯著成長，這主要得益於市場對創新疫苗解決方案的強勁需求。在該市場中，機器學習演算法表現最為突出，憑藉其先進的預測模型和數據分析能力，加速了疫苗研發進程。自然語言處理工具緊隨其後，能夠幫助處理大量的科學文獻。人工智慧在臨床試驗模擬的應用也日益普及，有助於最佳化試驗設計和病患招募策略。同時，人工智慧驅動的藥物發現領域也取得了顯著進展，利用深度學習更有效率地識別潛在候選疫苗。基於人工智慧的診斷工具正成為早期檢測和監測疫苗有效性的關鍵組成部分。隨著產業的不斷發展，人工智慧開發者與製藥公司之間日益密切的合作有望促進創新，並加速有效疫苗的上市進程。

市場區隔
類型 機器學習、深度學習、自然語言處理
產品 AI平台、AI工具、AI軟體
服務 諮詢、實施、支援和維護
科技 雲端部署、本地部署、混合部署
成分 硬體、軟體和服務
應用 藥物發現、臨床試驗、疫苗生產、預測分析
最終用戶 製藥公司、生技公司、研究機構、受託研究機構（CRO）
發展階段 臨床前、臨床、核准、上市後
實施表格 雲端、本地部署、混合部署
功能 數據分析、自動化報告和預測建模

人工智慧在疫苗研發領域的市場佔有率正經歷著動態變化，主要企業透過策略定價和創新產品推出不斷鞏固其市場地位。精準醫療的興起和疫苗生產速度的加快推動了人工智慧技術的應用。新興企業也紛紛湧入市場，利用尖端演算法最佳化疫苗效力。科技公司與大型製藥公司之間的合作進一步推動了這一趨勢，雙方旨在充分發揮人工智慧在藥物發現和研發方面的潛力。競爭基準分析顯示，儘管大型科技公司引領人工智慧整合的步伐，但生技公司也迅速跟進。監管，尤其是在北美和歐洲的監管，對塑造市場動態至關重要，以確保疫苗的安全性和有效性符合標準。這些監管措施透過強制遵守嚴格的通訊協定來鼓勵創新。隨著人工智慧不斷革新疫苗研發，在研發投入增加和技術進步的推動下，市場預計將迎來強勁成長。

主要趨勢和促進因素：

由於多項關鍵趨勢和促進因素，人工智慧在疫苗研發領域的市場正經歷顯著成長。人工智慧融入藥物發現流程，加速了疫苗研發進程。機器學習演算法最佳化了候選疫苗的選擇，降低了成本並提高了疫苗的有效性。這項技術進步正在重塑傳統的研發模式，使人們能夠快速應對新的健康威脅。此外，全球對疫情預防的日益重視也推動了對人工智慧疫苗研發的投資。各國政府和私營部門都在優先研發快速有效的疫苗，以遏止未來的疫情爆發。生物技術和人工智慧公司之間不斷增加的資金投入和合作正在促進創新，這種協同效應對於應對複雜的生物學挑戰至關重要。此外，隨著個人化醫療需求的成長，人工智慧正被用於開發針對個人基因譜量身定做的疫苗。這一趨勢正在提高疫苗接種策略的準確性和有效性。人工智慧在預測病毒變異方面的能力也蘊藏著許多機會，能夠確保疫苗對不斷演變的病原體的有效性。隨著這些趨勢和促進因素的不斷發展，人工智慧在疫苗研發領域的市場預計將持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 機器學習
    • 深度學習
    • 自然語言處理
  • 市場規模及預測：依產品分類
    • 人工智慧平台
    • 人工智慧工具
    • 人工智慧軟體
  • 市場規模及預測：依服務分類
    • 諮詢
    • 執行
    • 支援與維護
  • 市場規模及預測：依技術分類
    • 基於雲端的
    • 本地部署
    • 混合
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依應用領域分類
    • 藥物發現
    • 臨床試驗
    • 疫苗生產
    • 預測分析
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
    • 合約研究機構
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床領域
    • 核准
    • 售後
  • 市場規模及預測：依發展狀況
    • 雲
    • 本地部署
    • 混合
  • 市場規模及預測：依功能分類
    • 數據分析
    • 自動報告
    • 預測建模

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Benevolent AI
  • Exscientia
  • Atomwise
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • Xtal Pi
  • Valo Health
  • Cyclica
  • Deep Genomics
  • Healx
  • Bio Symetrics
  • Schrodinger
  • Verge Genomics
  • Peptilogics
  • Revive Med
  • Two XAR
  • Numerate
  • Inveni AI
  • Owkin
  • Lantern Pharma

第9章：關於我們

簡介目錄
Product Code: GIS32842

AI for Vaccine Development Market is anticipated to expand from $48.8 billion in 2024 to $449.6 billion by 2034, growing at a CAGR of approximately 29.4%. The AI for Vaccine Development Market encompasses the integration of artificial intelligence technologies in the research, design, and production of vaccines. AI accelerates vaccine discovery by analyzing vast datasets, predicting pathogen structures, and optimizing clinical trials. The market is driven by the need for rapid response to emerging diseases and the efficiency of AI in reducing time and cost in vaccine development. Key trends include AI-driven platforms for antigen discovery and personalized vaccine design, reflecting a shift towards precision medicine.

The AI for Vaccine Development Market is experiencing significant growth, primarily driven by the surge in demand for innovative vaccine solutions. Within this market, the machine learning algorithms segment is the top performer, offering advanced predictive models and data analysis capabilities that accelerate vaccine research. Natural language processing tools, which assist in processing vast amounts of scientific literature, follow as the second highest-performing segment. The integration of AI in clinical trial simulations is also gaining momentum, enhancing trial design and patient recruitment strategies. Meanwhile, the AI-driven drug discovery sub-segment is making substantial strides, leveraging deep learning to identify potential vaccine candidates more efficiently. AI-based diagnostic tools are emerging as a vital component, supporting early detection and monitoring of vaccine efficacy. As the industry evolves, the collaboration between AI developers and pharmaceutical companies is expected to intensify, fostering innovation and expediting the delivery of effective vaccines to the market.

Market Segmentation
TypeMachine Learning, Deep Learning, Natural Language Processing
ProductAI Platforms, AI Tools, AI Software
ServicesConsulting, Implementation, Support and Maintenance
TechnologyCloud-based, On-premise, Hybrid
ComponentHardware, Software, Services
ApplicationDrug Discovery, Clinical Trials, Vaccine Manufacturing, Predictive Analytics
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
StagePre-clinical, Clinical, Approval, Post-marketing
DeploymentCloud, On-premise, Hybrid
FunctionalityData Analysis, Automated Reporting, Predictive Modeling

AI for vaccine development is witnessing a dynamic shift in market share, with leading companies enhancing their foothold through strategic pricing and innovative product launches. The focus on precision medicine and accelerated vaccine production timelines has spurred the adoption of AI technologies. Emerging players are also entering the market, leveraging cutting-edge algorithms to optimize vaccine efficacy. This trend is further supported by collaborations between tech firms and pharmaceutical giants, aiming to harness AI's potential in drug discovery and development. Competitive benchmarking reveals that major tech companies are setting the pace in AI integration, while biotech firms are rapidly catching up. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, ensuring safety and efficacy standards are met. These regulations also drive innovation by necessitating compliance with stringent protocols. As AI continues to revolutionize vaccine development, the market is poised for robust growth, with increased investment in R&D and technological advancements.

Geographical Overview:

The AI for Vaccine Development Market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads the market, propelled by advanced AI technologies and substantial investments in healthcare research. The presence of major pharmaceutical companies and AI startups further accelerates growth. Europe follows, with strong governmental support for AI in healthcare, fostering a dynamic ecosystem for vaccine development. The region's focus on innovation and collaboration enhances its market potential. In the Asia Pacific, rapid technological advancements and increasing healthcare investments drive market expansion. Countries like China and India are emerging as key players, leveraging AI to expedite vaccine research and development. Latin America and the Middle East & Africa are burgeoning markets with significant opportunities. In Latin America, increasing public and private sector investments in AI are catalyzing growth. Meanwhile, the Middle East & Africa are recognizing AI's potential to revolutionize vaccine development, thereby boosting their healthcare sectors.

The AI for Vaccine Development Market is being intricately shaped by global tariff impacts and geopolitical risks, particularly in East Asia. Japan and South Korea, reliant on advanced AI technologies, are adapting to US-China trade tensions by enhancing domestic AI capabilities and fostering regional collaborations. China's focus on self-sufficiency is accelerating its AI innovation, while Taiwan's semiconductor prowess remains pivotal yet vulnerable to geopolitical pressures. The parent market for AI in healthcare is robust, driven by technological advancements and increased healthcare investments. By 2035, the market is poised for substantial growth, contingent on resilient supply chains and strategic partnerships. Additionally, Middle East conflicts could disrupt global supply chains and elevate energy prices, influencing operational costs and strategic planning in these nations.

Key Trends and Drivers:

The AI for Vaccine Development Market is experiencing remarkable growth due to several pivotal trends and drivers. The integration of artificial intelligence in drug discovery processes is accelerating vaccine development timelines. Machine learning algorithms are optimizing candidate selection, thereby reducing costs and improving efficacy. This technological advancement is reshaping traditional R&D frameworks, enabling rapid responses to emerging health threats. Moreover, the global emphasis on pandemic preparedness is driving investments in AI-driven vaccine research. Governments and private sectors are prioritizing swift and effective vaccine development to mitigate future outbreaks. Increased funding and collaboration between biotech firms and AI companies are fostering innovation. This synergy is crucial in addressing complex biological challenges. Additionally, the demand for personalized medicine is propelling the use of AI in tailoring vaccines to individual genetic profiles. This trend is enhancing the precision and effectiveness of immunization strategies. Opportunities abound in expanding AI capabilities to predict viral mutations, ensuring vaccines remain effective against evolving pathogens. The AI for Vaccine Development Market is poised for sustained growth as these trends and drivers continue to evolve.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Machine Learning
    • 4.1.2 Deep Learning
    • 4.1.3 Natural Language Processing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 AI Platforms
    • 4.2.2 AI Tools
    • 4.2.3 AI Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Implementation
    • 4.3.3 Support and Maintenance
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cloud-based
    • 4.4.2 On-premise
    • 4.4.3 Hybrid
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Drug Discovery
    • 4.6.2 Clinical Trials
    • 4.6.3 Vaccine Manufacturing
    • 4.6.4 Predictive Analytics
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Research Institutes
    • 4.7.4 Contract Research Organizations
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Pre-clinical
    • 4.8.2 Clinical
    • 4.8.3 Approval
    • 4.8.4 Post-marketing
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 Cloud
    • 4.9.2 On-premise
    • 4.9.3 Hybrid
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Data Analysis
    • 4.10.2 Automated Reporting
    • 4.10.3 Predictive Modeling

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
      • 5.2.1.9 Deployment
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
      • 5.2.2.9 Deployment
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
      • 5.2.3.9 Deployment
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
      • 5.3.1.9 Deployment
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
      • 5.3.2.9 Deployment
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
      • 5.3.3.9 Deployment
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
      • 5.4.1.9 Deployment
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
      • 5.4.2.9 Deployment
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
      • 5.4.3.9 Deployment
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
      • 5.4.4.9 Deployment
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
      • 5.4.5.9 Deployment
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
      • 5.4.6.9 Deployment
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
      • 5.4.7.9 Deployment
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
      • 5.5.1.9 Deployment
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
      • 5.5.2.9 Deployment
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
      • 5.5.3.9 Deployment
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
      • 5.5.4.9 Deployment
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
      • 5.5.5.9 Deployment
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
      • 5.5.6.9 Deployment
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
      • 5.6.1.9 Deployment
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
      • 5.6.2.9 Deployment
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
      • 5.6.3.9 Deployment
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
      • 5.6.4.9 Deployment
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Stage
      • 5.6.5.9 Deployment
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Benevolent AI
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Exscientia
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Atomwise
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Insilico Medicine
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Recursion Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Xtal Pi
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Valo Health
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cyclica
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Deep Genomics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Healx
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bio Symetrics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Schrodinger
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Verge Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Peptilogics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Revive Med
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Two XAR
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Numerate
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Inveni AI
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Owkin
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Lantern Pharma
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us